Tempus AI Unveils Paige Predict Pathology Solution and HRD-RNA Algorithm
Tempus AI integrates AI with multimodal healthcare data to enhance personalized diagnostics and treatment decisions. The company recently launched the Paige Predict digital pathology solution and HRD-RNA algorithm, and expanded partnerships with Merck and leading health systems to accelerate AI-driven oncology screening and research.
1. Platform Integration
Tempus AI combines clinical, molecular and imaging datasets with artificial intelligence to develop precision diagnostics that guide personalized treatment decisions. Its platform centralizes multimodal data to improve the accuracy of biomarker identification and therapy matching.
2. New Diagnostics Solutions
The company launched the Paige Predict digital pathology solution to automate tissue analysis and introduced the HRD-RNA algorithm for enhanced detection of homologous recombination deficiency. These innovations aim to streamline diagnostics workflows and improve early cancer detection rates.
3. Collaborations and Partnerships
Tempus AI expanded collaborations with Merck and major health systems to validate its AI-driven tools in clinical settings. These partnerships are expected to accelerate oncology research, broaden adoption of digital pathology and support large-scale screening initiatives.